Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 16;21(1):106.
doi: 10.1186/s12874-021-01298-7.

Methodology of the DCCSS later fatigue study: a model to investigate chronic fatigue in long-term survivors of childhood cancer

Adriaan Penson  1 , Sylvia van Deuren  2 , Ewald Bronkhorst  3 , Ellen Keizer  2 , Tom Heskes  4 , Marieke J H Coenen  5 , Judith G M Rosmalen  6 , Wim J E Tissing  7   8 , Helena J H van der Pal  7 , Andrica C H de Vries  9 , Marry M van den Heuvel-Eibrink  7   10 , Sebastian Neggers  7   11 , Birgitta A B Versluys  7 , Marloes Louwerens  12 , Margriet van der Heiden-van der Loo  13 , Saskia M F Pluijm  7 , Martha Grootenhuis  14 , Nicole Blijlevens  2 , Leontien C M Kremer  7   15 , Eline van Dulmen-den Broeder  16 , Hans Knoop  17 , Jacqueline Loonen  2
Affiliations

Methodology of the DCCSS later fatigue study: a model to investigate chronic fatigue in long-term survivors of childhood cancer

Adriaan Penson et al. BMC Med Res Methodol. .

Abstract

Background: A debilitating late effect for childhood cancer survivors (CCS) is cancer-related fatigue (CRF). Little is known about the prevalence and risk factors of fatigue in this population. Here we describe the methodology of the Dutch Childhood Cancer Survivor Late Effect Study on fatigue (DCCSS LATER fatigue study). The aim of the DCCSS LATER fatigue study is to examine the prevalence of and factors associated with CRF, proposing a model which discerns predisposing, triggering, maintaining and moderating factors. Triggering factors are related to the cancer diagnosis and treatment during childhood and are thought to trigger fatigue symptoms. Maintaining factors are daily life- and psychosocial factors which may perpetuate fatigue once triggered. Moderating factors might influence the way fatigue symptoms express in individuals. Predisposing factors already existed before the diagnosis, such as genetic factors, and are thought to increase the vulnerability to develop fatigue. Methodology of the participant inclusion, data collection and planned analyses of the DCCSS LATER fatigue study are presented.

Results: Data of 1955 CCS and 455 siblings was collected. Analysis of the data is planned and we aim to start reporting the first results in 2022.

Conclusion: The DCCSS LATER fatigue study will provide information on the epidemiology of CRF and investigate the role of a broad range of associated factors in CCS. Insight in associated factors for fatigue in survivors experiencing severe and persistent fatigue may help identify individuals at risk for developing CRF and may aid in the development of interventions.

Keywords: Associated factors; Cancer related fatigue; Childhood Cancer survivors; Chronic fatigue; Methodology; Multivariable fatigue model.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Hypothesized multivariable CRF model in CCS. Model showing associated factors of CRF divided into predisposing- (genetic factors and blood biomarkers which are thought to impact the vulnerability to fatigue), triggering- (factors related to the cancer diagnosis and treatment during childhood and are thought to trigger fatigue symptoms), maintaining- (daily life- and psychosocial factors which may perpetuate fatigue once triggered) and moderating factors (factors which might influence the way fatigue symptoms express in individuals). Continuous lines: factors that are hypothesized to be directly related to CRF. Dashed lines: factors that are hypothesized to possibly act as moderator or confounder for other factors, but might also directly be related to CRF. BMI: Body Mass Index. * Included comorbidities are categorized into the following main organ systems: Neoplasms, Cardiac-, vascular-, respiratory-, gastro-intestinal-, hepatobiliary-, renal and urinary tract-, endocrine-, musculoskeletal-, ear-, eye-, nervous system-, and other conditions
Fig. 2
Fig. 2
Flowcharts. a: Flowchart of the CCS participants. b: Flowchart of the sibling participants. IC – no participation: Gave consent, however did not participate. No/missing fat. Data: Did not complete the Checklist Individual Strength subscale fatigue (CIS-fatigue), or duration fatigue symptoms was unknown. When only one item of the CIS-fatigue was missing, the missing value was imputed with the mean score of the other seven items (n = 5 survivors and n = 3 siblings). Participants with two or more missing values on the CIS-fatigue were excluded
See this image and copyright information in PMC

References

    1. Coebergh JW, et al. Childhood cancer survival in Europe, 1978-1992: the EUROCARE study. Eur J Cancer. 2001;37(6):671–672. doi: 10.1016/S0959-8049(01)00005-3. - DOI - PubMed
    1. Sankila R, Martos Jiménez MC, Miljus D, Pritchard-Jones K, Steliarova-Foucher E, Stiller C. Geographical comparison of cancer survival in European children (1988–1997): report from the automated childhood Cancer information system project. Eur J Cancer. 2006;42(13):1972–1980. doi: 10.1016/j.ejca.2006.05.013. - DOI - PubMed
    1. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009;45(6):992–1005. 10.1016/j.ejca.2008.11.042. - PubMed
    1. Geenen MM, Cardous-Ubbink MC, Kremer LCM, van den Bos C, van der Pal HJH, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. Jama. 2007;297(24):2705–15. 10.1001/jama.297.24.2705. - PubMed
    1. Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer. 2002;38(1):27–43. doi: 10.1016/S0959-8049(01)00332-X. - DOI - PubMed

Publication types